Mimicry and well known genetic friends: molecular diagnosis in an Iranian cohort of suspected Bartter syndrome and proposition of an algorithm for clinical differential diagnosis.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
13 02 2019
Historique:
received: 23 06 2018
accepted: 14 12 2018
entrez: 15 2 2019
pubmed: 15 2 2019
medline: 20 4 2019
Statut: epublish

Résumé

Bartter Syndrome is a rare, genetically heterogeneous, mainly autosomal recessively inherited condition characterized by hypochloremic hypokalemic metabolic alkalosis. Mutations in several genes encoding for ion channels localizing to the renal tubules including SLC12A1, KCNJ1, BSND, CLCNKA, CLCNKB, MAGED2 and CASR have been identified as underlying molecular cause. No genetically defined cases have been described in the Iranian population to date. Like for other rare genetic disorders, implementation of Next Generation Sequencing (NGS) technologies has greatly facilitated genetic diagnostics and counseling over the last years. In this study, we describe the clinical, biochemical and genetic characteristics of patients from 15 Iranian families with a clinical diagnosis of Bartter Syndrome. Age range of patients included in this study was 3 months to 6 years and all patients showed hypokalemic metabolic alkalosis. 3 patients additionally displayed hypercalciuria, with evidence of nephrocalcinosis in one case. Screening by Whole Exome Sequencing (WES) and long range PCR revealed that 12/17 patients (70%) had a deletion of the entire CLCNKB gene that was previously identified as the most common cause of Bartter Syndrome in other populations. 4/17 individuals (approximately 25% of cases) were found to suffer in fact from pseudo-Bartter syndrome resulting from congenital chloride diarrhea due to a novel homozygous mutation in the SLC26A3 gene, Pendred syndrome due to a known homozygous mutation in SLC26A4, Cystic Fibrosis (CF) due to a novel mutation in CFTR and apparent mineralocorticoid excess syndrome due to a novel homozygous loss of function mutation in HSD11B2 gene. 1 case (5%) remained unsolved. Our findings demonstrate deletion of CLCNKB is the most common cause of Bartter syndrome in Iranian patients and we show that age of onset of clinical symptoms as well as clinical features amongst those patients are variable. Further, using WES we were able to prove that nearly 1/4 patients in fact suffered from Pseudo-Bartter Syndrome, reversing the initial clinical diagnosis with important impact on the subsequent treatment and clinical follow up pathway. Finally, we propose an algorithm for clinical differential diagnosis of Bartter Syndrome.

Sections du résumé

BACKGROUND
Bartter Syndrome is a rare, genetically heterogeneous, mainly autosomal recessively inherited condition characterized by hypochloremic hypokalemic metabolic alkalosis. Mutations in several genes encoding for ion channels localizing to the renal tubules including SLC12A1, KCNJ1, BSND, CLCNKA, CLCNKB, MAGED2 and CASR have been identified as underlying molecular cause. No genetically defined cases have been described in the Iranian population to date. Like for other rare genetic disorders, implementation of Next Generation Sequencing (NGS) technologies has greatly facilitated genetic diagnostics and counseling over the last years. In this study, we describe the clinical, biochemical and genetic characteristics of patients from 15 Iranian families with a clinical diagnosis of Bartter Syndrome.
RESULTS
Age range of patients included in this study was 3 months to 6 years and all patients showed hypokalemic metabolic alkalosis. 3 patients additionally displayed hypercalciuria, with evidence of nephrocalcinosis in one case. Screening by Whole Exome Sequencing (WES) and long range PCR revealed that 12/17 patients (70%) had a deletion of the entire CLCNKB gene that was previously identified as the most common cause of Bartter Syndrome in other populations. 4/17 individuals (approximately 25% of cases) were found to suffer in fact from pseudo-Bartter syndrome resulting from congenital chloride diarrhea due to a novel homozygous mutation in the SLC26A3 gene, Pendred syndrome due to a known homozygous mutation in SLC26A4, Cystic Fibrosis (CF) due to a novel mutation in CFTR and apparent mineralocorticoid excess syndrome due to a novel homozygous loss of function mutation in HSD11B2 gene. 1 case (5%) remained unsolved.
CONCLUSIONS
Our findings demonstrate deletion of CLCNKB is the most common cause of Bartter syndrome in Iranian patients and we show that age of onset of clinical symptoms as well as clinical features amongst those patients are variable. Further, using WES we were able to prove that nearly 1/4 patients in fact suffered from Pseudo-Bartter Syndrome, reversing the initial clinical diagnosis with important impact on the subsequent treatment and clinical follow up pathway. Finally, we propose an algorithm for clinical differential diagnosis of Bartter Syndrome.

Identifiants

pubmed: 30760291
doi: 10.1186/s13023-018-0981-5
pii: 10.1186/s13023-018-0981-5
pmc: PMC6375149
doi:

Substances chimiques

CLCNKB protein, human 0
Chloride Channels 0
Chloride-Bicarbonate Antiporters 0
SLC26A3 protein, human 0
SLC26A4 protein, human 0
Sulfate Transporters 0
11-beta-Hydroxysteroid Dehydrogenase Type 2 EC 1.1.1.146
HSD11B2 protein, human EC 1.1.1.146

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41

Subventions

Organisme : European Research Council
ID : 716344
Pays : International
Organisme : Deutsche Forschungsgemeinschaft
ID : CRC1140_KIDGEM
Pays : International

Références

J Med Genet. 1999 Aug;36(8):595-8
pubmed: 10465108
J Am Soc Nephrol. 2000 Aug;11(8):1449-59
pubmed: 10906158
Hum Mutat. 2001 Sep;18(3):233-42
pubmed: 11524734
Nat Genet. 2001 Nov;29(3):310-4
pubmed: 11687798
Lancet. 2002 Aug 31;360(9334):692-4
pubmed: 12241879
Hum Mutat. 2002 Dec;20(6):425-38
pubmed: 12442266
Kidney Int. 2003 Jan;63(1):24-32
pubmed: 12472765
Nephrol Dial Transplant. 2003 Sep;18(9):1696-700
pubmed: 12937211
Am J Med. 1962 Dec;33:811-28
pubmed: 13969763
Clin Genet. 2004 Oct;66(4):333-40
pubmed: 15355436
Hum Genet. 2005 Dec;118(3-4):331-8
pubmed: 16189704
Horm Res. 2006;65(2):62-8
pubmed: 16391491
J Am Soc Nephrol. 2006 Nov;17(11):3176-84
pubmed: 17035606
Acta Otolaryngol. 2008 Mar;128(3):297-303
pubmed: 18274916
J Med Genet. 2008 Mar;45(3):182-6
pubmed: 18310267
Clin Nephrol. 2008 Jun;69(6):450-3
pubmed: 18538122
Eur J Endocrinol. 2011 Jul;165(1):167-70
pubmed: 21551164
J Laryngol Otol. 2011 Sep;125(9):965-7
pubmed: 21745434
Turk J Gastroenterol. 2011 Jun;22(3):321-3
pubmed: 21805424
J Hum Hypertens. 2013 Aug;27(8):510-5
pubmed: 23303402
Clin Genet. 2013 Oct;84(4):388-91
pubmed: 23336812
Saudi J Kidney Dis Transpl. 2013 Mar;24(2):292-6
pubmed: 23538352
J Res Med Sci. 2013 Sep;18(9):822-4
pubmed: 24381629
Nephrol Dial Transplant. 2015 Aug;30(8):1257-66
pubmed: 25281699
World J Methodol. 2015 Jun 26;5(2):55-61
pubmed: 26140272
Srp Arh Celok Lek. 2015 Nov-Dec;143(11-12):748-51
pubmed: 26946774
N Engl J Med. 2016 May 12;374(19):1853-63
pubmed: 27120771
PLoS One. 2017 Mar 13;12(3):e0173581
pubmed: 28288174
Biophys Rev. 2009 Mar;1(1):3-12
pubmed: 28510151
Best Pract Res Clin Endocrinol Metab. 2017 Mar;31(2):213-224
pubmed: 28648509
Ann Biol Clin (Paris). 2017 Aug 1;75(4):466-473
pubmed: 28751295
Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11248-E11256
pubmed: 29229831
Bol Med Hosp Infant Mex. 2016 Sep - Oct;73(5):331-334
pubmed: 29384126
Front Med. 2018 Oct;12(5):550-558
pubmed: 29520692
Front Pediatr. 2018 Mar 14;6:58
pubmed: 29594088
Trans Assoc Am Physicians. 1966;79:221-35
pubmed: 5929460
Nat Genet. 1996 Jun;13(2):183-8
pubmed: 8640224
Nat Genet. 1996 Oct;14(2):152-6
pubmed: 8841184
J Am Soc Nephrol. 1997 Feb;8(2):352-5
pubmed: 9048354
Nat Genet. 1997 Oct;17(2):171-8
pubmed: 9326936
J Nephrol. 1998 Mar-Apr;11(2):61-9
pubmed: 9589375
Kidney Int. 1998 Oct;54(4):1396-410
pubmed: 9767561

Auteurs

Maryam Najafi (M)

Genome Research Division, Human Genetics department, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525KL, Nijmegen, The Netherlands.
Departement of Biology, University of Sistan and Baluchestan, Zahedan, Iran.

Dor Mohammad Kordi-Tamandani (DM)

Departement of Biology, University of Sistan and Baluchestan, Zahedan, Iran. dor_kordi@yahoo.com.

Farkhondeh Behjati (F)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Simin Sadeghi-Bojd (S)

Children and Adolescents Health Research Center, resistant tuberculosis institute, Zahedan University of Medical Sciences, Zahedan, Iran.

Zeineb Bakey (Z)

Genome Research Division, Human Genetics department, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525KL, Nijmegen, The Netherlands.
Center for Pediatrics and Adolescent Medicine, Freiburg University Hospital, Freiburg University Faculty of Medicine, Mathildenstrasse 1, 79112, Freiburg, Germany.

Ehsan Ghayoor Karimiani (EG)

Razavi Cancer Research, Razavi Hospital, Imam Reza International University, Mashhad, Iran.
Next Generation Genetic Polyclinic, Mashhad, Iran.

Isabel Schüle (I)

Center for Pediatrics and Adolescent Medicine, Freiburg University Hospital, Freiburg University Faculty of Medicine, Mathildenstrasse 1, 79112, Freiburg, Germany.

Anoush Azarfar (A)

Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Miriam Schmidts (M)

Genome Research Division, Human Genetics department, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525KL, Nijmegen, The Netherlands. miriam.schmidts@uniklinik-freiburg.de.
Center for Pediatrics and Adolescent Medicine, Freiburg University Hospital, Freiburg University Faculty of Medicine, Mathildenstrasse 1, 79112, Freiburg, Germany. miriam.schmidts@uniklinik-freiburg.de.
Center for Pediatrics and Adolescent Medicine, University Hospital Freiburg, 79112, Freiburg, Germany. miriam.schmidts@uniklinik-freiburg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH